Welcome to our dedicated page for Syros Pharmaceuticals news (Ticker: SYRS), a resource for investors and traders seeking the latest updates and insights on Syros Pharmaceuticals stock.
Syros Pharmaceuticals, Inc. (SYRS) is a pioneering life sciences company dedicated to transforming the treatment landscape for various diseases by strategically mapping gene regulatory circuits and modulating the factors that control gene expression. Syros stands out in the pharmaceutical industry for its groundbreaking gene control research and drug discovery capabilities, which integrate disease biology and genomic data in ways that are not commonly seen in traditional pharmaceutical R&D.
At the heart of Syros' innovative approach is a proprietary platform composed of advanced assay technologies, sophisticated bioinformatics, and deep biological insights. This platform, developed by Syros' seasoned senior leadership team, is designed to decode the complexities of gene regulation and uncover new therapeutic avenues.
While the scientific approach of Syros has broad applications across multiple therapeutic areas, the company has achieved notable success in oncology. Syros is working to address significant unmet medical needs, particularly in the treatment of hematologic malignancies, by developing new standards of care for frontline patient treatment.
Syros Pharmaceuticals is currently involved in several promising projects and partnerships aimed at advancing its clinical pipeline and expanding its impact on patient care. The company’s recent achievements and ongoing projects underscore its commitment to harnessing gene control research to develop innovative therapies.
Financially, Syros is strategically positioned to continue its research and development efforts, supported by robust funding and a clear vision for the future of precision medicine. With a focus on oncology, Syros continues to push the boundaries of what is possible in medical science, aiming to deliver groundbreaking treatments that can significantly improve patient outcomes.
Syros Pharmaceuticals (NASDAQ:SYRS) announced that its SELECT-MDS-1 Phase 3 trial of tamibarotene combined with azacitidine for newly diagnosed higher-risk myelodysplastic syndrome (HR-MDS) patients with RARA gene overexpression failed to meet its primary endpoint. The complete response rate in the treatment arm was 23.8% compared to 18.8% in the control arm, which was not statistically significant. The safety profile was generally well-tolerated. The company will discontinue the study and evaluate next steps. The trial failure triggers a default event under Syros' secured loan facility with Oxford Finance
Syros Pharmaceuticals reported Q3 2024 financial results, highlighting zero revenue compared to $3.8M in Q3 2023 due to Pfizer collaboration termination. R&D expenses decreased to $20.5M from $28.3M, while G&A expenses reduced to $5.7M from $7.8M. The company reported a net loss of $6.4M ($0.16 per share) versus $40.1M ($1.43 per share) in Q3 2023. Cash position stands at $58.3M, expected to fund operations into Q3 2025. Pivotal Complete Response data from SELECT-MDS-1 Phase 3 trial for tamibarotene in HR-MDS patients is expected mid-November 2024.
Syros Pharmaceuticals (NASDAQ:SYRS) has scheduled its third quarter 2024 financial results announcement and business update for Thursday, October 31, 2024, at 8:30 a.m. ET. The company will host a live conference call and webcast accessible via phone at (800) 549-8228 (domestic) or (289) 819-1520 (international) using conference ID 07454. A webcast replay will be available for approximately 30 days on the company's website.
Bronstein, Gewirtz & Grossman, is investigating potential claims on behalf of Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) stockholders. The investigation follows Syros' announcement on August 12, 2024, that it will discontinue enrollment in the SELECT-AML-1 Phase 2 clinical trial for acute myeloid leukemia (AML) treatment. This decision was based on a prespecified interim analysis indicating a low probability of demonstrating superiority at the final analysis.
Investors who purchased Syros securities are encouraged to assist the investigation by visiting bgandg.com/SYRS. The law firm represents investors in securities fraud class actions and shareholder derivative suits on a contingency fee basis, seeking reimbursement for expenses and attorneys' fees only if successful.
Bronstein, Gewirtz & Grossman, is investigating potential claims against Syros Pharmaceuticals, Inc. (NASDAQ:SYRS). The investigation follows Syros' announcement on August 12, 2024, that it will discontinue enrollment in the SELECT-AML-1 Phase 2 clinical trial for acute myeloid leukemia (AML) treatment. This decision was based on a prespecified interim analysis indicating a low probability of success in demonstrating superiority at the final analysis.
Investors who purchased Syros securities are encouraged to participate in the investigation. The law firm is offering its services on a contingency fee basis, meaning fees will only be charged if the case is successful. Bronstein, Gewirtz & Grossman, has a track record of recovering significant sums for investors in securities fraud class actions and shareholder derivative suits.
Bronstein, Gewirtz and Grossman, has launched an investigation into Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) on behalf of shareholders. The investigation follows Syros' announcement on August 12, 2024, that it will discontinue enrollment in the SELECT-AML-1 Phase 2 clinical trial for a triplet regimen treating acute myeloid leukemia (AML). This decision was based on a prespecified interim analysis indicating a low probability of success in demonstrating superiority at the final analysis.
Investors who purchased Syros securities are encouraged to participate in the investigation. The law firm is offering its services on a contingency fee basis, meaning fees will only be charged if the case is successful. Bronstein, Gewirtz & Grossman, has a track record of recovering significant sums for investors in securities fraud class actions and shareholder derivative suits.
Syros Pharmaceuticals (NASDAQ:SYRS) has announced its participation in two upcoming events. At the Society of Hematologic Oncology (SOHO) Annual Meeting from September 4-7 in Houston, Texas, Syros will present additional data from the randomized portion of the SELECT-AML-1 Phase 2 clinical trial. The presentation, titled 'SELECT-AML-1: Phase 2 Randomized Trial of Tamibarotene in Combination With Venetoclax and Azacitidine in Adult Patients With Previously Untreated AML With RARA Overexpression, Who Are Ineligible for Standard Induction Therapy', is scheduled for September 4, 2024, at 5:15-6:30 PM CT.
Additionally, Syros management will participate in the H.C. Wainwright 26th Annual Global Investment Conference on September 9, 2024, at 11:30 AM ET in New York City. A live webcast of this presentation will be available on the company's website, with an archived replay accessible for approximately 30 days afterward.
Bronstein, Gewirtz and Grossman, is investigating potential claims against Syros Pharmaceuticals, Inc. (NASDAQ:SYRS). The investigation follows Syros' announcement on August 12, 2024, that it will discontinue enrollment in the SELECT-AML-1 Phase 2 clinical trial for acute myeloid leukemia (AML) treatment. This decision was based on a prespecified interim analysis indicating a low probability of demonstrating superiority at the final analysis. Investors who purchased Syros securities are encouraged to participate in the investigation. The law firm is offering its services on a contingency fee basis, seeking reimbursement for expenses and attorneys' fees only if successful.
Bronstein, Gewirtz & Grossman, is investigating potential claims against Syros Pharmaceuticals, Inc. (NASDAQ:SYRS). The investigation follows Syros' announcement on August 12, 2024, that it will discontinue enrollment in the SELECT-AML-1 Phase 2 clinical trial for a triplet regimen in acute myeloid leukemia (AML) patients. This decision was based on a prespecified interim analysis indicating a low probability of success in demonstrating superiority at the final analysis.
Investors who purchased Syros securities are encouraged to participate in the investigation. The law firm is offering its services on a contingency fee basis, meaning fees will only be charged if the case is successful. Bronstein, Gewirtz & Grossman, has a track record of recovering significant sums for investors in securities fraud class actions and shareholder derivative suits.
Syros Pharmaceuticals (NASDAQ:SYRS) announced the discontinuation of enrollment in its SELECT-AML-1 Phase 2 clinical trial for acute myeloid leukemia (AML) treatment. The trial compared a triplet regimen (tamibarotene, venetoclax, and azacitidine) to a doublet regimen (venetoclax and azacitidine) in newly diagnosed, unfit AML patients with RARA gene overexpression.
The decision was based on a prespecified interim analysis of 51 patients, which showed similar complete response rates in both arms (65% triplet vs. 70% doublet). No new safety concerns were identified. Syros will present the trial data at the SOHO Annual Meeting in September 2024.
Despite this setback, Syros remains committed to evaluating tamibarotene in combination with azacitidine for higher-risk myelodysplastic syndrome (MDS) in the ongoing SELECT-MDS-1 Phase 3 trial, with pivotal data expected by mid-fourth quarter 2024.
FAQ
What is the current stock price of Syros Pharmaceuticals (SYRS)?
What is the market cap of Syros Pharmaceuticals (SYRS)?
What does Syros Pharmaceuticals specialize in?
What is unique about Syros Pharmaceuticals' approach?
In which therapeutic areas has Syros Pharmaceuticals shown success?
What recent achievements has Syros Pharmaceuticals made?
What is the financial condition of Syros Pharmaceuticals?
What is the proprietary platform of Syros Pharmaceuticals?
How does Syros Pharmaceuticals impact patient treatment?
Where is Syros Pharmaceuticals making its mark in the pharmaceutical industry?
Who are the key contributors to Syros Pharmaceuticals' proprietary platform?
What is the mission of Syros Pharmaceuticals?
